Deals with the cost-effectiveness of the drug eluting heart stent developed by Johnson & Johnson in March 2003.EBSCO_bspWall Street Journal - Eastern Edition
Text EnglishEspañolDeutschFrançaisItalianoالعربية中文简体PolskiPortuguêsNederlandsNorskΕλληνικήРусскийTürkçeאנגלית 9 RegisterLog in Sign up with one click: Facebook Twitter Google Share on Facebook ...
- 《American Heart Journal》 被引量: 102发表: 2008年 The role of everolimus-eluting and resolute zotarolimus-eluting stents in the treatment of coronary bifurcations. To compare the long-term clinical outcomes of everolimus-eluting (EES) and Resolute zotarolimus-eluting (R-ZES) stents in the ...
Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007;28(6):719-25... BL Rocca,C Kaiser,M Pfisterer - 《European Heart Journal》 被引量: 111发表: 2007年 Incremental cost-effectiveness of drug-eluting stents compar...
- 《British Heart Journal》 被引量: 116发表: 1980年 Risks and benefits of aortocoronary bypass surgery in patients aged 65 years or more Between January 1970 and July 1978, 85 patients aged 65 years or more underwent aortocoronary bypass surgery at the Montreal Heart Institute. The mortality....
This survey revealed no marked differences in long-term HRQOL between patients who underwent Palmaz-Schatz coronary stenting compared with those who underwent conventional angioplasty. (Am Heart J 1997;134:337-44.) 展开 关键词: reperfusion apoptosis conduction ...
- 《European Heart Journal Acute Cardiovascular Care》 被引量: 0发表: 2022年 Abstract 4141854: Paclitaxel Coated versus Uncoated Balloon for Coronary In-stent Restenosis: A Systematic Review and Meta-Analysis with Trial Sequential A... Background:Drug-coated balloons present a potentially advantageous...
Cardiovascular disease, including atherosclerosis, is the leading cause of death in the U.S. The medical community has developed a number of methods and devices for treating coronary heart disease, some of which are specifically designed to treat the complications resulting from atherosclerosis and oth...
Therefore, the risk and cost of implanting additional DES in such cases should be weighed against the risk of subsequent clinical events. Predictors Predictive factors for DES restenosis, such as diabetes mellitus, complex lesions (B2/C), small vessels, longer stents, and stent underexpansion, ...
The term expensive refers to the cost which can be computational cost or cost of physical experiments. Non-dominated solution is a set of optimised design solutions, whereby no solution is better than any other member in all optimisation objectives. 2. Key developments from past to current ...